March 18 (Reuters) - Arvinas Inc ARVN.O:
ARVINAS ANNOUNCES POSITIVE PHASE 1 DATA FOR ARV-102 SHOWING GREATER THAN 50% LRRK2 DEGRADATION IN THE CSF OF PATIENTS WITH PARKINSON’S DISEASE TREATED FOR 28 DAYS
ARVINAS INC - NO SERIOUS ADVERSE EVENTS, DISCONTINUATIONS, OR DEATHS REPORTED WITH ARV-102
ARVINAS INC: ARV-102 WAS WELL TOLERATED ACROSS ALL DOSE LEVELS FOLLOWING 28 DAYS OF ONCE-DAILY DOSING
ARVINAS INC - PLANS PHASE 1B TRIAL OF ARV-102 IN PSP IN Q2 2026